1-3 of 3
Andrew Wotherspoon
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

MRI Tumor Regression Grade and Circulating Tumor DNA as Complementary Tools to Assess Response and Guide Therapy Adaptation in Rectal Cancer

Shelize Khakoo, Paul David Carter, Gina Brown, Nicola Valeri, Simona Picchia, Maria Antonietta Bali, Ridwan Shaikh, Thomas Jones, Ruwaida Begum, Isma Rana, Andrew Wotherspoon, Monica Terlizzo, Katharina von Loga, Eleftheria Kalaitzaki, Claire Saffery, David Watkins, Diana Tait, Ian Chau, Naureen Starling, Michael Hubank, David Cunningham
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (1): 183–192.
https://doi.org/10.1158/1078-0432.CCR-19-1996
Published: 03 January 2020
View article titled, MRI Tumor Regression Grade and Circulating Tumor DNA as Complementary Tools to Assess Response and Guide Therapy Adaptation in Rectal Cancer
Open the PDF for MRI Tumor Regression Grade and Circulating Tumor DNA as Complementary Tools to Assess Response and Guide Therapy Adaptation in Rectal Cancer in another window
Includes: Supplementary data
Journal Articles

Pharmacogenetic Analysis of the UK MRC (Medical Research Council) MAGIC Trial: Association of Polymorphisms with Toxicity and Survival in Patients Treated with Perioperative Epirubicin, Cisplatin, and 5-fluorouracil (ECF) Chemotherapy

Elizabeth Smyth, Shenli Zhang, David Cunningham, Andrew Wotherspoon, Richie Soong, Clare Peckitt, Nicola Valeri, Matteo Fassan, Massimo Rugge, Alicia Okines, William Allum, Sally Stenning, Matthew Nankivell, Ruth Langley, Patrick Tan
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (24): 7543–7549.
https://doi.org/10.1158/1078-0432.CCR-16-3142
Published: 14 December 2017
View article titled, Pharmacogenetic Analysis of the UK MRC (Medical Research Council) MAGIC Trial: Association of Polymorphisms with Toxicity and Survival in Patients Treated with Perioperative Epirubicin, Cisplatin, and 5-fluorouracil (ECF) Chemotherapy
Open the PDF for Pharmacogenetic Analysis of the UK MRC (Medical Research Council) MAGIC Trial: Association of Polymorphisms with Toxicity and Survival in Patients Treated with Perioperative Epirubicin, Cisplatin, and 5-fluorouracil (ECF) Chemotherapy in another window
Includes: Supplementary data
Journal Articles

FcγRIIa and Fc γ RIIIa Polymorphisms and Cetuximab Benefit in the Microscopic Disease

Francesco Sclafani, David Gonzalez de Castro, David Cunningham, Sanna Hulkki Wilson, Clare Peckitt, Jaume Capdevila, Bengt Glimelius, Susana Roselló Keränen, Andrew Wotherspoon, Gina Brown, Diana Tait, Ruwaida Begum, Janet Thomas, Jacqueline Oates, Ian Chau
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (17): 4511–4519.
https://doi.org/10.1158/1078-0432.CCR-14-0674
Published: 01 September 2014
View article titled, <em>FcγRIIa</em> and <em>Fc <em>γ</em> RIIIa</em> Polymorphisms and Cetuximab Benefit in the Microscopic Disease
Open the PDF for <em>FcγRIIa</em> and <em>Fc <em>γ</em> RIIIa</em> Polymorphisms and Cetuximab Benefit in the Microscopic Disease in another window